Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2016

01-10-2016 | Original Article

Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma

Authors: A. C. Mamede, S. Guerra, M. Laranjo, K. Santos, M. J. Carvalho, T. Carvalheiro, P. Moura, A. Paiva, A. M. Abrantes, C. J. Maia, M. F. Botelho

Published in: Pathology & Oncology Research | Issue 4/2016

Login to get access

Abstract

The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor.
Literature
1.
Toda A, Okabe M, Yoshida T, Nikaido T (2007) The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci 105:215–228CrossRefPubMed
2.
Davis J (1910) Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med J 15:307
3.
Gomes J, Romano A, Santos M, Dua H (2005) Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol 16:233–240CrossRefPubMed
4.
5.
Sawhney C (1989) Amniotic membrane as a biological dressing in the management of burns. Burns 15:339–342CrossRefPubMed
6.
Mamede A, Carvalho M, Abrantes A, et al. (2012) Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res 349:447–458CrossRefPubMed
7.
Magatti M, De Munari S, Vertua E, Parolini O (2012) Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. J Cell Mol Med 16:2208–2218CrossRefPubMedPubMedCentral
8.
Jiao H, Guan F, Yang B, et al. (2012) Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the bcl-2/caspase pathways. Mol Biol Rep 39:467–473CrossRefPubMed
9.
Rolfo A, Giuffrida D, Giuffrida M, et al. (2014) New perspectives for prostate cancer treatment: in vitro inhibition of LNCaP and PC3 cell proliferation by amnion-derived mesenchymal stromal cells conditioned media. Aging Male 17:94–101CrossRefPubMed
10.
Kang N-H, Yi B-R, Lim S, et al. (2012) Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int J Oncol 40:2022–2028PubMed
11.
Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H (2014) Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. Cytotherapy 16:33–40CrossRefPubMed
12.
Mamede A, Laranjo M, Carvalho M, et al. (2014) Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study. J Membr Biol 247:357–360CrossRefPubMed
13.
Mamede A, Guerra S, Laranjo M, et al. (2015) Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma. Med Oncol 32:257CrossRefPubMed
14.
Gomes M, Priolli D, Tralhão J, Botelho M (2013) Hepatocellular carcinoma: epidemiology, biology, diagnosis and therapies. Rev Assoc Med Bras 59:514–524CrossRefPubMed
15.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMed
16.
Marra M, Sordelli I, Lombardi A, et al. (2011) Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 9:171CrossRefPubMedPubMedCentral
17.
Alves R, Alves D, Guz B, et al. (2011) Advanced hepatocellular carcinoma: review of targeted molecular drugs. Ann Hepatol 10:21–27PubMed
18.
Brito A, Abrantes A, Pinto-Costa C, et al. (2013) Hepatocellular carcinoma and chemotherapy: the role of p53. Chemotherapy 58:381–386CrossRef
19.
Tralhão J, Abrantes A, Hoti E, et al. (2013) Hepatectomy and liver regeneration: from experimental research to clinical application. ANZ J Surg 84:665–671CrossRefPubMed
20.
Abrantes A, Serra M, Gonçalves A, et al. (2010) Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells. Nucl Med Biol 37:125–132CrossRefPubMed
21.
Tralhão J, Abrantes A, Gonçalves A, et al. (2013) Study of hepatocellular function in the murine model following hepatic artery selective clamping. Acta Cir Bras 28:657–663CrossRefPubMed
22.
Gomes A, Fernandes E, Lima J (2005) Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods 65:45–80CrossRefPubMed
23.
Mamede A, Pires A, Abrantes A, et al. (2012) Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies. Nutr Cancer 64:1049–1057CrossRefPubMed
24.
Larrauri A, López P, Gómez-Lechón M, Castell J (1987) A cytochemical stain for glutathione in rat hepatocytes cultured on plastic. J Histochem Cytochem 35:271–274CrossRefPubMed
25.
26.
Santos K, Laranjo M, Abrantes A, et al. (2014) Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles. Eur J Med Chem 79:273–281CrossRefPubMed
27.
Serra A, Am RG, Laranjo M, et al. (2012) Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. antitumor evaluation against melanoma and breast cancer cells. Eur J Med Chem 53:398–402CrossRefPubMed
28.
Brito A, Abrantes A, Ribeiro M, et al. (2015) Fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma: correlation with glucose transporters and p53 expression. J Clin Exp Hepatol 5:183–189CrossRefPubMedPubMedCentral
29.
30.
Brito A, Mendes M, Abrantes A, et al. (2014) Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)fluoro-d-glucose. Mol Diagn Ther 18:495–504CrossRefPubMed
31.
Casalta-Lopes J, Abrantes A, Laranjo M, et al. (2011) Efflux pumps modulation in colorectal adenocarcinoma cell lines: the role of nuclear medicine. J Cancer Ther 02:408–417CrossRef
32.
Choi K, Kim J, Kim G, Choi C (2009) Oxidative stress-induced necrotic cell death via mitochondira-dependent burst of reactive oxygen species. Curr Neurovasc Res 6:213–222CrossRefPubMed
33.
Valko M, Leibfritz D, Moncol J, et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84CrossRefPubMed
34.
Li Y, Schellhorn H (2007) New developments and novel therapeutic perspectives for vitamin C. J Nutr 137:2171–2184PubMed
35.
Georgiou C, Papapostolou I, Grintzalis K (2009) Protocol for the quantitative assessment of DNA concentration and damage (fragmentation and nicks). Nat Protoc 4:125–131CrossRefPubMed
36.
37.
Oberhammer F, Wilson J, Dive C, et al. (1993) Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12:3679–3684PubMedPubMedCentral
38.
Zamai L, Falcieri E, Marhefka G, Vitale M (1996) Supravital exposure to propidium iodide identifies apoptotic cells in the absence of nucleosomal DNA fragmentation. Cytometry 23:303–311CrossRefPubMed
39.
Macleod K, Sherry N, Hannon G, et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935–944CrossRefPubMed
40.
Hussain S, Schwank J, Staib F, et al. (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26:2166–2176CrossRefPubMed
41.
Cayrol C, Knibiehler M, Ducommun B (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16:311–320CrossRefPubMed
42.
Punchihewa C, Inoue A, Hishiki A, et al. (2012) Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem 287:14289–14300CrossRefPubMedPubMedCentral
43.
Stark G, Taylor W (2004) Analyzing the G2/M checkpoint. In: Schonthal AH (ed) Checkp. Control. cancer Rev. Model Syst. Humana Press, Totowa, pp. 51–82
44.
Wu G, Xu L, Lin N, Liu B (2013) UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer 13:167CrossRefPubMedPubMedCentral
45.
Chan K-T, Lung M (2004) Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53:519–526CrossRefPubMed
46.
Tsang W-P, Chau S, Fung K-P, et al. (2003) Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in saos-2 cells. Cancer Chemother Pharmacol 51:161–166PubMed
Metadata
Title
Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma
Authors
A. C. Mamede
S. Guerra
M. Laranjo
K. Santos
M. J. Carvalho
T. Carvalheiro
P. Moura
A. Paiva
A. M. Abrantes
C. J. Maia
M. F. Botelho
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0053-x

Other articles of this Issue 4/2016

Pathology & Oncology Research 4/2016 Go to the issue

Original Article

P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas

Review

Phytochemicals in the Fight Against Cancer

Original Article

The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines

Original Article

Genetic Polymorphism of SUMO-Specific Cysteine Proteases − SENP1 and SENP2 in Breast Cancer

Original Article

Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells

Original Article

Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits